fbpx
Wikipedia

Mirogabalin

January 01, 1970

Mirogabalin (brand name Tarlige; developmental code name DS-5565) is a gabapentinoid medication developed by Daiichi Sankyo. Gabapentin and pregabalin are also members of this class. As a gabapentinoid, mirogabalin binds to the α2δ subunit of voltage-gated calcium channel (1 and 2), but with significantly higher potency than pregabalin. It has shown promising results in Phase II clinical trials for the treatment of diabetic peripheral neuropathic pain.[1][2]

Mirogabalin
Clinical data
Trade namesTarlige
Other namesDS-5565
Routes of
administration		By mouth
ATC code
Identifiers
  • (1R,5S,6S)-6-(aminomethyl)-3-ethyl-bicyclo(3.2.0)hept-3-ene-6-acetic acid
CAS Number
  • 1138245-13-2 Y
PubChem CID
  • 49802951
ChemSpider
  • 32701007
UNII
  • S7LK2KDM5U
KEGG
  • D11203
CompTox Dashboard (EPA)
  • DTXSID001032301
Chemical and physical data
FormulaC12H19NO2
Molar mass209.289 g·mol−1
3D model (JSmol)
  • Interactive image
  • CCC1=CC2C(C1)C[C@@]2(CN)CC(=O)O
  • InChI=1S/C12H19NO2/c1-2-8-3-9-5-12(7-13,6-11(14)15)10(9)4-8/h4,9-10H,2-3,5-7,13H2,1H3,(H,14,15)/t9-,10-,12-/m1/s1
  • Key:FTBQORVNHOIASH-CKYFFXLPSA-N

Phase III trial results:

In Japan, the company submitted a marketing application for treatment of peripheral neuropathic pain.[5] The medication was approved for neuropathic pain and postherpetic neuralgia in Japan in January 2019.[6]

References edit

  1. ^ Vinik A, Rosenstock J, Sharma U, Feins K, Hsu C, Merante D (December 2014). "Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study". Diabetes Care. 37 (12): 3253–61. doi:10.2337/dc14-1044. PMID 25231896.
  2. ^ Vinik A, Sharma U, Feins K, Hsu C, Merante D (2014). "DS-5565 for the Treatment Of Diabetic Peripheral Neuropathic Pain: Randomized, Double-Blind, Placebo- And Active Comparator-Controlled Phase II Study (S20.004)". Neurology. 82 (10): S20.004.
  3. ^ "Daiichi Sankyo Announces Top-line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes". Daiichi Sankyo. 30 June 2017.
  4. ^ "Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Clinical Trial Evaluating Mirogabalin in Diabetic Peripheral Neuropathic Pain". Daiichi Sankyo. 31 August 2017.
  5. ^ "Daiichi Sankyo Submits Marketing Application for Mirogabalin in Japan". Daiichi Sankyo. 15 February 2018.
  6. ^ "Mirogabalin - Daiichi Sankyo Company - AdisInsight".

External links edit

  • "Mirogabalin". Drug Information Portal. U.S. National Library of Medicine.


 

This analgesic-related article is a stub. You can help Wikipedia by expanding it.

January 01, 1970
mirogabalin, brand, name, tarlige, developmental, code, name, 5565, gabapentinoid, medication, developed, daiichi, sankyo, gabapentin, pregabalin, also, members, this, class, gabapentinoid, mirogabalin, binds, α2δ, subunit, voltage, gated, calcium, channel, wi. Mirogabalin brand name Tarlige developmental code name DS 5565 is a gabapentinoid medication developed by Daiichi Sankyo Gabapentin and pregabalin are also members of this class As a gabapentinoid mirogabalin binds to the a2d subunit of voltage gated calcium channel 1 and 2 but with significantly higher potency than pregabalin It has shown promising results in Phase II clinical trials for the treatment of diabetic peripheral neuropathic pain 1 2 MirogabalinClinical dataTrade namesTarligeOther namesDS 5565Routes ofadministrationBy mouthATC codeN02BF03 WHO IdentifiersIUPAC name 1R 5S 6S 6 aminomethyl 3 ethyl bicyclo 3 2 0 hept 3 ene 6 acetic acidCAS Number1138245 13 2 YPubChem CID49802951ChemSpider32701007UNIIS7LK2KDM5UKEGGD11203CompTox Dashboard EPA DTXSID001032301Chemical and physical dataFormulaC 12H 19N O 2Molar mass209 289 g mol 13D model JSmol Interactive imageSMILES CCC1 CC2C C1 C C 2 CN CC O OInChI InChI 1S C12H19NO2 c1 2 8 3 9 5 12 7 13 6 11 14 15 10 9 4 8 h4 9 10H 2 3 5 7 13H2 1H3 H 14 15 t9 10 12 m1 s1Key FTBQORVNHOIASH CKYFFXLPSA N Phase III trial results Effective for post herpetic neuralgia trial NEUCOURSE Ineffective for fibromyalgia trial ALDAY 3 Effective for diabetic peripheral neuropathic pain trial REDUCER 4 In Japan the company submitted a marketing application for treatment of peripheral neuropathic pain 5 The medication was approved for neuropathic pain and postherpetic neuralgia in Japan in January 2019 6 References edit Vinik A Rosenstock J Sharma U Feins K Hsu C Merante D December 2014 Efficacy and safety of mirogabalin DS 5565 for the treatment of diabetic peripheral neuropathic pain a randomized double blind placebo and active comparator controlled adaptive proof of concept phase 2 study Diabetes Care 37 12 3253 61 doi 10 2337 dc14 1044 PMID 25231896 Vinik A Sharma U Feins K Hsu C Merante D 2014 DS 5565 for the Treatment Of Diabetic Peripheral Neuropathic Pain Randomized Double Blind Placebo And Active Comparator Controlled Phase II Study S20 004 Neurology 82 10 S20 004 Daiichi Sankyo Announces Top line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes Daiichi Sankyo 30 June 2017 Daiichi Sankyo Announces Positive Top line Results from Phase 3 Clinical Trial Evaluating Mirogabalin in Diabetic Peripheral Neuropathic Pain Daiichi Sankyo 31 August 2017 Daiichi Sankyo Submits Marketing Application for Mirogabalin in Japan Daiichi Sankyo 15 February 2018 Mirogabalin Daiichi Sankyo Company AdisInsight External links edit Mirogabalin Drug Information Portal U S National Library of Medicine Portal nbsp Medicine nbsp This analgesic related article is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Mirogabalin amp oldid 1181715279, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.